JP2016527202A5 - - Google Patents

Download PDF

Info

Publication number
JP2016527202A5
JP2016527202A5 JP2016519586A JP2016519586A JP2016527202A5 JP 2016527202 A5 JP2016527202 A5 JP 2016527202A5 JP 2016519586 A JP2016519586 A JP 2016519586A JP 2016519586 A JP2016519586 A JP 2016519586A JP 2016527202 A5 JP2016527202 A5 JP 2016527202A5
Authority
JP
Japan
Prior art keywords
amount
compound
cancer
administration
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016519586A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016527202A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/041643 external-priority patent/WO2014200969A2/en
Publication of JP2016527202A publication Critical patent/JP2016527202A/ja
Publication of JP2016527202A5 publication Critical patent/JP2016527202A5/ja
Pending legal-status Critical Current

Links

JP2016519586A 2013-06-10 2014-06-10 癌の治療方法 Pending JP2016527202A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361833186P 2013-06-10 2013-06-10
US61/833,186 2013-06-10
PCT/US2014/041643 WO2014200969A2 (en) 2013-06-10 2014-06-10 Methods of treatment of cancer

Publications (2)

Publication Number Publication Date
JP2016527202A JP2016527202A (ja) 2016-09-08
JP2016527202A5 true JP2016527202A5 (https=) 2017-07-20

Family

ID=52022914

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016519586A Pending JP2016527202A (ja) 2013-06-10 2014-06-10 癌の治療方法

Country Status (4)

Country Link
US (1) US20170035917A1 (https=)
EP (1) EP3008212A4 (https=)
JP (1) JP2016527202A (https=)
WO (1) WO2014200969A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014321711B2 (en) 2013-09-19 2019-11-14 The Research Foundation For The State University Of New York Methods and materials for treating diabetes or liver steatosis
US10639322B2 (en) 2015-03-27 2020-05-05 The Research Foundation For The State University Of New York Methods and materials for reducing amyloid beta levels within a mammal
JP6793180B2 (ja) * 2015-03-27 2020-12-02 ザ リサーチ ファウンデーション フォー ザ ステイト ユニバーシティ オブ ニューヨーク 癌を治療するための方法および物質
US12287389B1 (en) * 2015-07-31 2025-04-29 Fonar Corporation Method and system for monitoring effectiveness of a treatment regimen
EP4649966A3 (en) 2016-12-01 2026-02-18 Regeneron Pharmaceuticals, Inc. Radiolabeled anti-pd-l1 antibodies for immuno-pet imaging
EA201991673A1 (ru) 2017-02-10 2020-01-17 Регенерон Фармасьютикалз, Инк. Меченные радиоактивным изотопом антитела к lag3 для иммуно-пэт-визуализации
SG11202000073XA (en) 2017-07-24 2020-02-27 Regeneron Pharma Anti-cd8 antibodies and uses thereof
EP3793614A4 (en) 2018-04-30 2022-04-20 Integral Molecular, Inc. GLUCOSE TRANSPORTER-4 ANTIBODIES, PROCESSES FOR THEIR PRODUCTION AND THEIR USES
CN109053782B (zh) * 2018-08-09 2020-01-17 潍坊博创国际生物医药研究院 多功能靶向免疫小分子抗癌药枸橼酸Bestazomib及其制备方法与应用
AU2020349462A1 (en) 2019-09-16 2022-03-03 Regeneron Pharmaceuticals, Inc. Radiolabeled MET binding proteins for immuno-PET imaging

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100111856A1 (en) * 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
EP2730579A1 (en) * 2008-06-17 2014-05-14 Millennium Pharmaceuticals, Inc. Boronate ester compounds and pharmaceutical compositions thereof
CA2809362C (en) * 2010-08-24 2020-03-10 University Of Pittsburgh - Of The Commonwealth System Of Higher Educatn Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines
RU2013112156A (ru) * 2010-09-21 2014-10-27 ДжиИ ХЕЛТКЕР ЛИМИТЕД Аналоги холина в качестве радиоактивного индикатора
AU2011339929B2 (en) * 2010-12-06 2017-05-11 Tom C. Tsang Methods of metabolic targeting cancer cells using chemo- and immunotherapy for treating cancer
WO2013028907A1 (en) * 2011-08-23 2013-02-28 Infinity Pharmaceuticals, Inc. Biomarkers predictive of therapeutic responsiveness to hsp90 inhibitors and uses thereof
PL2753334T3 (pl) * 2011-08-30 2022-12-12 Trustees Of Tufts College Aktywowane przez fap inhibitory proteasomu do leczenia guzów litych
CN104039328B (zh) * 2011-11-11 2018-10-09 米伦纽姆医药公司 对蛋白酶体抑制剂的反应的生物标记

Similar Documents

Publication Publication Date Title
JP2016527202A5 (https=)
US11707539B2 (en) FAP-targeted radiopharmaceuticals and imaging agents, and uses related thereto
JP2014510728A5 (https=)
JP7169297B2 (ja) 再発膠芽腫（ｒｇｂｍ）の治療方法
RU2762193C2 (ru) Применение антагонистов рецептора ep4 для лечения nash-ассоциированного рака печени
JP2015536964A5 (https=)
KR20160066554A (ko) 브루톤 타이로신 키나제 억제제 및 면역요법을 이용한 치료
JP2010270124A5 (https=)
RU2019142507A (ru) Композиции, способы и системы для синтеза и применение визуализирующих средств
JP2015212268A5 (https=)
KR20200104291A (ko) 항암제
JP2014513089A5 (https=)
JP2012255026A5 (https=)
JP2018035162A5 (https=)
JP2018508516A5 (https=)
JP2011529968A5 (https=)
JP2015522033A5 (https=)
MX2013013014A (es) Metodo para el tratamiento de tumores solidos avanzados.
JP2014512355A5 (https=)
JP2019530706A5 (https=)
EP4578461A3 (en) Methods of treating parkinsons disease by administration of apomorphine to an oral mucosa
JP2018531605A5 (https=)
TW201141472A (en) Method to treat small cell lung cancer
JP7568309B2 (ja) 癌を処置する方法
JP2015515974A5 (https=)